Saniona: SAN903 Ready for the Clinic - Redeye

Redeye endorses Saniona’s pre-clinical progress with drug candidate SAN903, that has compelling anti-inflammatory and anti-fibrotic properties. Potential indications include inflammatory bowel disease and fibrotic disorders such as chronic kidney disease and idiopathic pulmonary fibrosis (“IPF”). The company now guides that it is ready to start the regulatory process for a first clinical study. We will review our valuation in relation to Saniona’s Q3 report and likely raise our base case to account for recent pipeline progress.

Länk till analysen i sin helhet: https://www.redeye.se/research/861182/saniona-san903-ready-for-the-clinic?utm_source=finwire&utm_medium=RSS